Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New-Gen Devices Offer Sleep Apnea Patients Alternative CPAP Routes

Executive Summary

With half or more of all diagnosed obstructive sleep apnea patients who need continuous positive airway pressure machines unwilling or unable to use these devices, there’s a large unmet need for an alternative treatment. Startups are rising to the challenge with neuromodulation platforms, a mouthguard-like suction device, a nasal device with microblowers, and a vibrating device that nudges patients to turn on their sides.

You may also be interested in...



ResMed Jumps On Board As Nyxoah Raises €25m For Neurostim Apnea Device

The proceeds from the investment will enable Nyxoah to prepare for the IDE pivotal trial of the Genio system in the US, and accelerate market access and commercialization activities in Europe, Australia and New Zealand.

ResMed, Verily Connect To Form Sleep Apnea JV

Sleep disorder therapy specialist ResMed and Alphabet's health unit Verily are combining their expertise to form a new joint venture focused on developing solutions that will enable health care providers to better diagnose and manage sleep apnea and other breathing-related sleep problems.

Electroceuticals: Drug-Like Effects, Without The Drugs

Electroceuticals could replace the use of pharmaceuticals in many chronic diseases, offering effective treatments without, perhaps, side effects. Medtechs pioneering these next-gen neuromodulation devices are sparking investor interest.

Topics

Related Companies

UsernamePublicRestriction

Register

MT103993

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel